Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVZO-021 + sacituzumab govitecan-hziy
- Development stage
- Unknown
- Lead developer
- Avenzo Therapeutics
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Oral, Intravenous
01
Overview
**AVZO-021 + sacituzumab govitecan-hziy** is an investigational combination therapy currently in clinical trials for the treatment of advanced solid tumors, with a focus on hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. AVZO-021 is a highly selective, oral cyclin-dependent kinase 2 (CDK2) inhibitor. Sacituzumab govitecan-hziy is a Trop-2-directed antibody-drug conjugate (ADC), consisting of a humanized monoclonal antibody targeting Trop-2 conjugated to the cytotoxic agent SN-38, a topoisomerase I inhibitor. The rationale for the combination is to enhance anti-tumor activity by simultaneously inhibiting cell cycle progression and targeting Trop-2-positive cancer cells with cytotoxic payload. The combination is being evaluated in an ongoing Phase 1/2 clinical trial[2][4].
- Brand names
- Trodelvy
- Other names
- sacituzumab govitecanTrodelvy
02
Targets
TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)CDK2 (Cyclin-dependent kinase 2)
Beyond the preview
Go deeper on AVZO-021 + sacituzumab govitecan-hziy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVZO-021 + sacituzumab govitecan-hziy.